Class Action Lawsuit Filed Against ImmunityBio, Inc. Over Alleged Securities Fraud
A class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) alleging securities fraud and unlawful business practices. The lawsuit follows a public warning letter from the FDA regarding misleading promotions of the company's drug Anktiva, which led to a 21.12% drop in the stock price on March 24, 2026. Investors are being urged to contact the law firm for potential involvement in the class action.
Tickers: $IBRX
Topics: class action FDA warning regulatory action securities fraud stock price drop